Company intelligence / Profile preview

Scailyte

Basel, Basel-Stadt, Switzerland

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Scailyte, an ETH Zürich spin-out, is a biotech platform company focused on discovering novel diagnostic and companion diagnostic assays using single-cell multi-omics and explainable AI. Its ScaiVision platform has enabled the development of robust, clinically validated assays for diagnosis and patient stratification in areas such as endometriosis (assets transferred to Hera Biotech), oncology, and autoimmunity. These assays have been validated on large single-cell datasets and clinical endpoints, with product launches anticipated or recently executed through technology transfer and partnership.

Therapeutic areas: OncologyWomen's HealthImmunology
Modalities: Diagnostic assayCompanion diagnostic assay
Industry: Molecular Diagnostics

Partnerships

VisterraHera Biotech

Beyond the preview

Go deeper on Scailyte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scailyte.

Explore the full profile